{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:04:50Z","timestamp":1780031090027,"version":"3.53.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":237,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006710","name":"Wayne State University","doi-asserted-by":"publisher","award":["S10OD030484"],"award-info":[{"award-number":["S10OD030484"]}],"id":[{"id":"10.13039\/100006710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006710","name":"Wayne State University","doi-asserted-by":"publisher","award":["P30ES036084"],"award-info":[{"award-number":["P30ES036084"]}],"id":[{"id":"10.13039\/100006710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009528","name":"Children's Hospital of Michigan Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017302","name":"Barbara Ann Karmanos Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD030484"],"award-info":[{"award-number":["S10OD030484"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30ES036084"],"award-info":[{"award-number":["P30ES036084"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA022453"],"award-info":[{"award-number":["P30CA022453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ASPET Discovery"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.aspetd.2025.100014","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:35:22Z","timestamp":1756856122000},"page":"100014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7706-4784","authenticated-orcid":false,"given":"Nibal","family":"Eid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Thibodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-8536","authenticated-orcid":false,"given":"Xun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Polin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juiwanna","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijana H.","family":"Dzinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B.","family":"Back","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Stemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1716-0913","authenticated-orcid":false,"given":"Maurgan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-073X","authenticated-orcid":false,"given":"Seongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.aspetd.2025.100014_bib1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.aspetd.2025.100014_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00277-008-0605-6","article-title":"Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells","volume":"88","author":"Weisel","year":"2009","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.aspetd.2025.100014_bib3","article-title":"FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies","volume":"15","author":"Jalte","year":"2023","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.aspetd.2025.100014_bib4","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","article-title":"Clinical implications of FLT3 mutations in pediatric AML","volume":"108","author":"Meshinchi","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.aspetd.2025.100014_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-020-00888-w","article-title":"Pharmacokinetic profile of gilteritinib: a novel FLT-3 tyrosine kinase inhibitor","volume":"59","author":"James","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"23","key":"10.1016\/j.aspetd.2025.100014_bib6","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.aspetd.2025.100014_bib7","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1182\/bloodadvances.2022007952","article-title":"BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors","volume":"6","author":"Buelow","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.aspetd.2025.100014_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.aspetd.2025.100014_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-021-00502-7","article-title":"The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML","volume":"11","author":"Qiao","year":"2021","journal-title":"Blood Cancer J"},{"issue":"11-12","key":"10.1016\/j.aspetd.2025.100014_bib10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10495-022-01756-7","article-title":"c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia","volume":"27","author":"Liu","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.aspetd.2025.100014_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-014-0053-9","article-title":"CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells","volume":"7","author":"Qi","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.aspetd.2025.100014_bib12","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/0008-5472.CAN-23-2659","article-title":"The imipridone ONC213 targets alpha-ketoglutarate dehydrogenase to induce mitochondrial stress and suppress oxidative phosphorylation in acute myeloid leukemia","volume":"84","author":"Su","year":"2024","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.aspetd.2025.100014_bib13","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2014.72","article-title":"Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199","volume":"28","author":"Niu","year":"2014","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.aspetd.2025.100014_bib14","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2008-09-179812","article-title":"RUNX1 regulates phosphoinositide 3-kinase\/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia","volume":"114","author":"Edwards","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.aspetd.2025.100014_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017138","article-title":"Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells","volume":"6","author":"Xu","year":"2011","journal-title":"PLOS One"},{"issue":"4","key":"10.1016\/j.aspetd.2025.100014_bib16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.aspetd.2025.100014_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116065","article-title":"Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax","volume":"228","author":"Zhao","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.aspetd.2025.100014_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115283","article-title":"Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia","volume":"205","author":"Hege Hurrish","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.aspetd.2025.100014_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115981","article-title":"Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and\/or purine biosynthesis in vitro","volume":"220","author":"Hurrish","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.aspetd.2025.100014_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jnci\/dji026","article-title":"GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia","volume":"97","author":"Ge","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.aspetd.2025.100014_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13059-021-02540-7","article-title":"Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects","volume":"22","author":"Dempster","year":"2021","journal-title":"Genome Biol"},{"key":"10.1016\/j.aspetd.2025.100014_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107547","article-title":"Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML","volume":"144","author":"Wu","year":"2024","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.aspetd.2025.100014_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51","volume":"8","author":"Xie","year":"2013","journal-title":"PLOS One"},{"issue":"5","key":"10.1016\/j.aspetd.2025.100014_bib24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2141.2007.06696.x","article-title":"Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells","volume":"138","author":"Kim","year":"2007","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.aspetd.2025.100014_bib25","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1111\/jcmm.15281","article-title":"CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: antitumour activity and molecular mechanism of action","volume":"24","author":"Hu","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"8","key":"10.1016\/j.aspetd.2025.100014_bib26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.aspetd.2025.100014_bib27","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3892\/ijo.2015.2912","article-title":"Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma","volume":"46","author":"Iwamoto","year":"2015","journal-title":"Int J Oncol"},{"issue":"13","key":"10.1016\/j.aspetd.2025.100014_bib28","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-13-0073","article-title":"RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy","volume":"19","author":"Rahman","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.aspetd.2025.100014_bib29","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/jcmm.17274","article-title":"Venetoclax enhances DNA damage induced by XPO1 inhibitors: a novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia","volume":"26","author":"Yu","year":"2022","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.aspetd.2025.100014_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117076","article-title":"Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells","volume":"177","author":"Hieber","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.aspetd.2025.100014_bib31","first-page":"104","article-title":"Gilteritinib: a novel FLT3 inhibitor for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Marjoncu","year":"2020","journal-title":"J Adv Pract Oncol"},{"issue":"23","key":"10.1016\/j.aspetd.2025.100014_bib32","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2021005164","article-title":"Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia","volume":"5","author":"McCall","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.aspetd.2025.100014_bib33","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/s41467-022-31489-9","article-title":"Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3\/ITD allelic ratios","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.aspetd.2025.100014_bib34","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","article-title":"Morphologic remission status is limited compared to DeltaN flow cytometry: a Children's Oncology Group AAML0531 report","volume":"4","author":"Brodersen","year":"2020","journal-title":"Blood Adv"}],"container-title":["ASPET Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050567425000136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050567425000136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:47:00Z","timestamp":1780030020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050567425000136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"alternative-id":["S3050567425000136"],"URL":"https:\/\/doi.org\/10.1016\/j.aspetd.2025.100014","relation":{},"ISSN":["3050-5674"],"issn-type":[{"value":"3050-5674","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ribonucleotide reductase to enhance the antileukemic activity of gilteritinib against chemoresistant FLT3- internal tandem duplication acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"ASPET Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aspetd.2025.100014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100014"}}